Abstract: Cyclin-dependent kinase 2 (CDK2) is a critical regulator of the cell cycle, specifically driving the G1-S phase transition. Dysregulation of the CDK2 signaling pathway, often through cyclin E overactivity, is implicated in various malignancies, including lung, breast, and ovarian cancers. Tagtociclib (PF-07104091) is a novel, selective CDK2 inhibitor currently undergoing clinical evaluation. This review synthesizes available clinical data on PF-07104091, highlighting its pharmacological activity, safety profile, and preliminary efficacy in advanced solid tumors. While the specific Phase 1 trial for PF-07104091 enrolled patients with small-cell lung cancer, breast cancer, and ovarian cancer, the broader class of CDK2 inhibitors has also demonstrated preliminary activity in non-small cell lung cancer (NSCLC). Despite promising early results, challenges such as gastrointestinal toxicity, fatigue, and acquired resistance necessitate the exploration of biomarker-driven patient selection and rational combination therapies.
1. Introduction
Cyclin-dependent kinase 2 (CDK2) plays a fundamental role in enforcing cell cycle progression, specifically regulating the transition from the G1 phase into the synthesis (S) phase [1]. Alterations in the CDK2 signaling pathway, such as abnormal CDK2 activity or high levels of cyclin E, are associated with genomic instability and oncogenesis in a variety of solid tumors, including lung, breast, ovarian, and colorectal cancers [1]. Because CDK2 signaling can also serve as a mechanism of resistance to CDK4/6 inhibitors, targeting CDK2 has emerged as a promising therapeutic strategy in oncology.
Tagtociclib, designated as PF-07104091, is a highly selective CDK2 inhibitor developed by Pfizer [1]. It is currently being investigated in clinical trials for patients with advanced or metastatic solid tumors. While the research direction of CDK2 inhibition extends to non-small cell lung cancer (NSCLC)—with other CDK2/9 inhibitors like fadraciclib showing tumor reduction in squamous NSCLC—the initial Phase 1/2a clinical trial for PF-07104091 specifically enrolled patients with advanced or metastatic small-cell lung cancer, breast cancer, and ovarian cancer [1].
2. Pharmacological Activity
The pharmacological profile and clinical activity of PF-07104091 were evaluated in a Phase 1/2a first-in-human clinical trial (NCT04553133) as a monotherapy. The trial enrolled 35 patients with advanced or metastatic small-cell lung, breast, or ovarian cancers, with a median age of 62 years [1]. The drug was administered orally at doses ranging from 75 to 500 mg twice daily (BID) in 28-day cycles [1].
Pharmacokinetic analyses revealed that PF-07104091 is rapidly absorbed, with a median time to maximum concentration (Tmax) of 0.5 to 4 hours. The mean effective half-life of the compound is approximately 2 to 3 hours, and steady-state plasma exposure increases proportionally with the administered dose [1]. The maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D) for monotherapy expansion were established at 300 mg BID [1].
In terms of antitumor activity, PF-07104091 demonstrated early signs of efficacy. Pharmacodynamic monitoring showed an early trend of decreased circulating tumor DNA (ctDNA) levels between day 1 and day 15 of the first cycle in evaluable patients treated at doses of ≥150 mg BID [1]. Among 16 response-evaluable patients with metastatic breast cancer, three achieved objective partial responses (PR) and six achieved stable disease (SD), resulting in a disease control rate of 61.5% [1].
3. Molecular Mechanism of Action
The molecular mechanism of PF-07104091 is rooted in the selective inhibition of CDK2. Under normal physiological conditions, the tumor suppressor protein Rb regulates the G1-S phase transition. When Rb is phosphorylated by the cyclin E/CDK2 complex, it de-represses E2F transcription factors. These factors induce the transcription of genes essential for the G1-S transition, overriding cell cycle checkpoints and preventing apoptosis [1].
In many cancers, overactivation of CDK2 leads to excessive phosphorylation of Rb, resulting in a premature and unregulated G1-S transition. This unregulated progression prevents cells from repairing damaged DNA before the S phase, leading to mutations, genomic instability, and the prevention of cellular senescence [1]. By selectively inhibiting CDK2, Tagtociclib (PF-07104091) blocks the hyperphosphorylation of Rb, thereby halting the release of E2F transcription factors, inducing cell cycle arrest at the G1 phase, and suppressing tumor proliferation [1].
4. Structure-Activity Relationship (SAR)
The provided literature focuses on the clinical trial outcomes, safety profiles, and biological rationale of CDK2 inhibitors in oncology. It does not contain specific chemical structure details or Structure-Activity Relationship (SAR) data for Tagtociclib (PF-07104091) [1].
5. Current Limitations
Despite its promising clinical activity, the use of PF-07104091 is associated with several limitations, primarily related to toxicity and the potential for acquired resistance.
Toxicity Profile: In the Phase 1 trial, 34 out of 35 patients experienced treatment-emergent adverse events (TEAEs). The most frequent TEAEs included nausea (77.1%), diarrhea (48.6%), vomiting (48.6%), fatigue (45.7%), and anemia (45.7%) [1]. Dose-limiting toxicities (DLTs) were observed in five patients at doses of 300 mg to 500 mg BID, which included Grade 3 fatigue, nausea, and anorexia [1]. While selective CDK2 inhibitors generally show a tolerable safety profile, PF-07104091 exhibited a trend of higher-grade severity in adverse events compared to some other agents in its class, which may reflect the greater dose intensity achieved in its trials [1].
Resistance Mechanisms: Preclinical studies indicate that resistance to CDK2 inhibitors can develop through the upregulation of CDK2 target proteins or due to preexisting cellular polyploidy [1]. Furthermore, because the objective response rate for selective CDK2 inhibitors as a monotherapy remains relatively low across broader unselected populations, monotherapy may not be sufficient for long-term disease control [1].
6. Future Perspectives
The future development of Tagtociclib (PF-07104091) and other CDK2 inhibitors in lung cancer and other solid tumors relies heavily on biomarker-driven patient selection and rational combination therapies.
Biomarker Development: Identifying patients most likely to benefit from CDK2 inhibition is a major priority. Potential biomarkers include CCNE1 (cyclin E1) amplification, which is a strong predictor of response to CDK2 inhibition across various tumor types. Other promising biomarkers under investigation include cyclin E1/2 overexpression, cyclin E1 mutations, CDK2 overexpression, FBXW7 loss, and USP28 overexpression [1].
Combination Therapies: To overcome resistance and improve efficacy, PF-07104091 is currently being investigated in various drug combinations. Because CDK2 signaling is a known mechanism of resistance to CDK4/6 inhibitors, pairing PF-07104091 with CDK4/6 inhibitors (such as the CDK4 inhibitor PF-07220060) is a highly anticipated strategy [1]. Additionally, dose expansions are ongoing for PF-07104091 in combination with endocrine therapies like fulvestrant and letrozole [1]. For lung and ovarian cancers, preclinical evidence suggests that combining CDK2 inhibitors with cytotoxic chemotherapy (e.g., carboplatin, gemcitabine) or PARP inhibitors could induce sustained tumor regression, paving the way for future clinical trial designs in NSCLC and other malignancies [1].
